ArticleStem cell reviews and reports2026
Generation and Exosomal Noncoding RNA Profiling of Down Syndrome-Specific Induced Pluripotent Stem Cells.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Down syndrome (DS) is a relatively severe chromosomal disorder marked by multiple significant clinical abnormalities. Currently, there is a need for the development of novel screening methods that utilize ideal cells, animal models, and clinical samples. In this study, we collected residual samples from clinical chromosome karyotyping analyses. Utilizing reprogramming technology with four transcription factors—KLF4, OCT4, c-MYC, and SOX2—we successfully generated Down syndrome-specific induced pluripotent stem cells (iPSCs). Flow cytometry and G-banding karyotyping validation confirmed that all established cell lines expressed pluripotency markers (TRA-1-81, SSEA4) and retained the characteristic karyotype (47,XY,+21). Subsequently, we isolated exosomes from the culture supernatant of DS-iPSCs. Microarray analysis revealed 595 differentially expressed non-coding RNAs (ncRNA), comprising 210 upregulated and 175 downregulated pre-miRNAs, as well as 123 upregulated and 87 downregulated small nucleolar RNAs (snoRNAs). Functional enrichment analysis indicated that these ncRNAs are primarily involved in key biological processes such as gene silencing, gene expression regulation, and peptide biosynthesis. Structural similarity analysis suggested that hsa-let-7c shares primary and secondary structural features with certain snoRNAs. Reverse transcription droplet digital PCR (RT-ddPCR) validation confirmed the upregulation of multiple pre-miRNAs, including hsa-let-7c, in the peripheral blood of mothers carrying DS fetuses. Overall, this study suggests that exosomal ncRNAs derived from DS-iPSCs may serve as potential targets for future biomarker discovery in DS diagnosis. This finding offers a novel approach for biomarker screening in diseases where obtaining clinical samples is challenging.
Indexed as
Identifiers
41578097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.